scholarly journals Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy

Molecules ◽  
2019 ◽  
Vol 24 (3) ◽  
pp. 429 ◽  
Author(s):  
Sefan Asamitsu ◽  
Shunsuke Obata ◽  
Zutao Yu ◽  
Toshikazu Bando ◽  
Hiroshi Sugiyama
Keyword(s):  
Nucleic Acid ◽  
Secondary Structure ◽  
Recent Progress ◽  
Development Process ◽  
Protein Targeting ◽  
Molecular Probe ◽  
Drug Development Process ◽  
Quadruplex Structure ◽  
G4 Dna ◽  
G Quadruplex

A G-quadruplex (G4) is a well-known nucleic acid secondary structure comprising guanine-rich sequences, and has profound implications for various pharmacological and biological events, including cancers. Therefore, ligands interacting with G4s have attracted great attention as potential anticancer therapies or in molecular probe applications. To date, a large variety of DNA/RNA G4 ligands have been developed by a number of laboratories. As protein-targeting drugs face similar situations, G-quadruplex-interacting drugs displayed low selectivity to the targeted G-quadruplex structure. This low selectivity could cause unexpected effects that are usually reasons to halt the drug development process. In this review, we address the recent research on synthetic G4 DNA-interacting ligands that allow targeting of selected G4s as an approach toward the discovery of highly effective anticancer drugs.

scholarly journals G4IPDB: A database for G-quadruplex structure forming nucleic acid interacting proteins

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Subodh Kumar Mishra ◽  
Arpita Tawani ◽  
Amit Mishra ◽  
Amit Kumar
Keyword(s):  
Nucleic Acid ◽  
Interacting Proteins ◽  
Quadruplex Structure ◽  
G Quadruplex

scholarly journals S phase R-loop formation is restricted by PrimPol-mediated repriming

2018 ◽  
Author(s):  
Saša Šviković ◽  
Alastair Crisp ◽  
Sue Mei Tan-Wong ◽  
Thomas A. Guilliam ◽  
Aidan J. Doherty ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Secondary Structure ◽  
Genetic Instability ◽  
S Phase ◽  
Loop Formation ◽  
Dna Motifs ◽  
G Quadruplex ◽  
Nucleic Acid Structures ◽  
Careful Management

SummaryDuring DNA replication, conflicts with ongoing transcription are frequent and require careful management to avoid genetic instability. R-loops, three stranded nucleic acid structures comprising a DNA:RNA hybrid and displaced single stranded DNA, are important drivers of damage arising from such conflicts. How R-loops stall replication and the mechanisms that restrain their formation during S phase are incompletely understood. Here we show in vivo how R-loop formation drives a short purine-rich repeat, (GAA)10, to become a replication impediment that requires the repriming activity of the primase-polymerase PrimPol for its processive replication. Further, we show that loss of PrimPol results in a significant increase in R-loop formation around the repeat during S phase. We extend this observation by showing that PrimPol suppresses R-loop formation in genes harbouring secondary structure-forming sequences, exemplified by G quadruplex and H-DNA motifs, across the genome in both avian and human cells. Thus, R-loops promote the creation of replication blocks at susceptible sequences, while PrimPol-dependent repriming limits the extent of unscheduled R-loop formation at these sequences, mitigating their impact on replication.

A Water-Soluble, Octacationic Zinc Phthalocyanine as Molecular Probe for Nucleic Acid Secondary Structure

2007 ◽  
Vol 4 (2) ◽  
pp. 215-223 ◽  
Author(s):  
An-Ming Zhang ◽  
Jing Huang ◽  
Xiao-Cheng Weng ◽  
Jin-Xi Li ◽  
Li-Ge Ren ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Secondary Structure ◽  
Water Soluble ◽  
Zinc Phthalocyanine ◽  
Molecular Probe

scholarly journals G-Quadruplex targeting ligands: A hope and a new horizon in Cancer Therapeutics

2018 ◽  
Author(s):  
Nilanjan Banerjee ◽  
Suman Panda ◽  
Subhrangsu Chatterjee
Keyword(s):  
Secondary Structure ◽  
Cancer Treatment ◽  
Small Molecules ◽  
Human Genome ◽  
Cancer Therapeutics ◽  
Structural Diversity ◽  
Quadruplex Structure ◽  
G Quadruplex ◽  
Therapeutic Research ◽  
Widespread Interest

G-quadruplex, a unique secondary structure in nucleic acids found throughout human genome elicited widespread interest in the field of therapeutic research. Being present in key regulatory regions of oncogenes, G-quadruplex structure regulates transcription, translation, splicing, telomere stability etc. Changes in its structure and stability lead to differential expression of oncogenes causing cancer. Thus, targeting G-Quadruplex structures with small molecules/ other biologics has shown elevated research interest. Covering previous reports, in this review we try to enlighten the facts on the structural diversity in G-quadruplex ligands aiming to provide newer insights to design first-in-class drugs for the next generation cancer treatment.

A Comparative Study of Pharmaceutical Incentives to Patents in India, USA and Europe

2020 ◽  
Vol 07 ◽  
Author(s):  
Renu Kadian ◽  
Arun Nanda
Keyword(s):  
United States ◽  
European Union ◽  
Intellectual Property Rights ◽  
United States Of America ◽  
Financial Support ◽  
Development Process ◽  
The United States ◽  
Drug Development Process ◽  
Data Exclusivity ◽  
Patent Term

Background:: Protection of Intellectual Property Rights is a clear incentive to innovations; yet, several countries have provided further incentives to patents in pharmaceuticals because the full patent term of 20 years is largely exhausted, before marketing authorization. Objective:: The purpose of this article is to describe the various incentives to patents in the form of financial support, data exclusivity and most importantly extended market exclusivities and comparison of various incentives to patents in the United States of America, European Union and India. Methodology:: The detail of incentives is collected from various articles, latest topics, books, and newspapers. Result:: These incentives create a positive surrounding to encourage the drug development process, strengthen economic growth and improve a balance between new pharmaceuticals in the market and access of that medicine to general public at a reasonable price. Conclusion:: European Union and the United States of America are leading in the field of incentives to patenting in phar-maceuticals as compared to India. Indian Patent Act, 1970, needs to be re-looked in terms of data exclusivity and patent term extensions.

Intelligent Drug Development

2014 ◽  
Author(s):  
Michael Tansey
Keyword(s):  
Clinical Trials ◽  
Cost Effectiveness ◽  
Drug Development ◽  
Clinical Research ◽  
Development Process ◽  
Drug Development Process ◽  
Individual Trial ◽  
Specific Technology

Clinical research is heavily regulated and involves coordination of numerous pharmaceutical-related disciplines. Each individual trial involves contractual, regulatory, and ethics approval at each site and in each country. Clinical trials have become so complex and government requirements so stringent that researchers often approach trials too cautiously, convinced that the process is bound to be insurmountably complicated and riddled with roadblocks. A step back is needed, an objective examination of the drug development process as a whole, and recommendations made for streamlining the process at all stages. With Intelligent Drug Development, Michael Tansey systematically addresses the key elements that affect the quality, timeliness, and cost-effectiveness of the drug-development process, and identifies steps that can be adjusted and made more efficient. Tansey uses his own experiences conducting clinical trials to create a guide that provides flexible, adaptable ways of implementing the necessary processes of development. Moreover, the processes described in the book are not dependent either on a particular company structure or on any specific technology; thus, Tansey's approach can be implemented at any company, regardless of size. The book includes specific examples that illustrate some of the ways in which the principles can be applied, as well as suggestions for providing a better context in which the changes can be implemented. The protocols for drug development and clinical research have grown increasingly complex in recent years, making Intelligent Drug Development a needed examination of the pharmaceutical process.

Sign in / Sign up

Export Citation Format

Share Document